We provide you with 20 years of free, institutional-grade data for HEPA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HEPA. Explore the full financial landscape of HEPA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Hepion Pharmaceuticals, Inc(NASDAQ:HEPA) 
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways inv...
Website: http://contravir.com/
Founded: 2013
Full Time Employees: 12
CEO: Robert Foster
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about HEPA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.